| Document |
Document Title |
|
WO/2024/094637A1 |
The present invention relates to a process for the preparation of cyclobutenone derivatives of formula (1), wherein Y is O or NH, R is -C(O)-R1 or -S(0)2-R1, and R' is selected from optionally substituted linear or branched C1-12 alkyl, ...
|
|
WO/2024/080603A1 |
The present invention relates to a method for preparing terephthalylidene dicamphor sulfonic acid using electrodialysis. The method for preparing terephthalylidene dicamphor sulfonic acid of the present invention supplies a solution cont...
|
|
WO/2024/070091A1 |
Provided are: a compound suitable for use as a photoacid generator for resist compositions that has favorable sensitivity to actinic energy such as EB and EUV, has excellent resolution in lithography, and can reduce line width roughness ...
|
|
WO/2024/071281A1 |
The purpose of the present invention is to provide: a novel asymmetric fluorinated allyl compound that can be induced to various bioactive medium-sized molecules, and that has high optical purity; and a method for producing the same. Asy...
|
|
WO/2024/068553A1 |
The present invention relates to tertiary amide compounds of formula (II), or a pharmaceutically acceptable salt thereof, wherein R7 comprises a group X which is -S(=O)2OH, -S(=O)OH or -P(=O)(OH)2- The compounds are capable of solubilizi...
|
|
WO/2024/053718A1 |
The present invention employs a resist composition that contains a resin component having a constituent unit represented by general formula (a0-1). In formula (a0-1), R01 is a divalent linking group or a single bond. R02 is an acid-disso...
|
|
WO/2024/048925A1 |
The present invention relates to an organic salt of terephthalylidene dicamphor sulfonic acid, which would be useful in cosmetic compositions for blocking ultraviolet rays, and a preparation method therefor. The present invention provide...
|
|
WO/2024/042157A1 |
Disclosed herein is a compound, or a pharmaceutically acceptable salt thereof, in particular hydrochloride salt thereof, characterized in that said compound is selected from the following compounds: - 4-(4-((1-(3-fluoropropyl)azetidin-3-...
|
|
WO/2024/043121A1 |
The present invention employs a resist composition including: a base material component, the solubility of said base material component in a developing fluid changing due to the action of an acid; and a compound represented by general fo...
|
|
WO/2024/040182A1 |
Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine or a pharmaceutically acceptable thereof to treat cancers and precancer lesions, including cancers and precancer lesions associated with papilloma virus ...
|
|
WO/2024/032081A1 |
The present invention provides a preparation method for semaglutide, and an intermediate. The preparation method comprises the steps of: (1) reacting compound SEM110 and compound SEM120 in a solvent under an alkaline condition to obtain ...
|
|
WO/2024/029354A1 |
Provided is a novel compound that has photosensitivity such that said compound rapidly decomposes and generates an acid when irradiated with light rays having a wavelength of 20 nm or lower. A sulfonium salt according to the present in...
|
|
WO/2024/027690A1 |
The present invention provides an intermediate of a bicyclic inhibitor and a preparation method therefor. The present invention particularly relates to an intermediate as shown in formula (VI) and a preparation method therefor. The react...
|
|
WO/2024/029351A1 |
Provided is a fluorene compound having a sulfonic acid ester structure and an allyl group, the compound being represented by formula (1). (In the formula, R1 each independently are a hydrogen atom or a methyl group. R2 each independently...
|
|
WO/2024/024703A1 |
The present invention relates to a resist composition that generates an acid by exposure to light, and that exhibits a change in solubility to a liquid developer through the action of the acid. The resist composition contains a base mate...
|
|
WO/2024/024692A1 |
Provided are a resist film, a pattern formation method, an electronic device manufacturing method that includes the pattern formation method, and an active light-sensitive or radiation-sensitive resin composition satisfying the following...
|
|
WO/2024/023489A1 |
The present invention provides a N-acylated taurine composition comprising: (a) a first N-acylated taurine compound of the formula (IA) or a salt thereof: and (b) a second N-acylated taurine compound of the formula (IB) or a salt thereof...
|
|
WO/2024/018395A1 |
The invention provides methods and certain intermediates for preparing 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2- yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H- benzimidazole-6-carboxylic acid 1,3-dihydroxy-2-(hydroxymeth...
|
|
WO/2024/014462A1 |
This resist composition comprises a resin component (A1) that exhibits change in solubility in a developing solution due to the action of an acid. The resin component (A1) has a constitution unit (a0) derived from a compound represented ...
|
|
WO/2024/012244A1 |
Embodiments of the present application provide a local high-concentration electrolyte, a secondary battery, an electronic device, and a mobile apparatus. The local high-concentration electrolyte comprises an electrolyte salt, an organic ...
|
|
WO/2024/011238A2 |
Provided herein are compounds and compositions that inhibit production of trimethylamine (TMA), and methods of using the compounds, e.g., for inhibiting production of trimethylamine, and for treating disorders associated with conversion ...
|
|
WO/2024/002786A1 |
The present invention relates to sulfonated and sulfated compounds obtainable from aryl aliphatic ketones, a process to produce such compounds and the use of these compounds as surfactants, alone or in admixture with other surfactants.
|
|
WO/2024/000060A1 |
The present invention provides novel salts of belumosudil (I) and crystalline forms thereof. Specific salts of belumosudil provided by the present invention include L-malate, acesulfamate, fumarate, maleate, isethionate, malonate, edisyl...
|
|
WO/2024/006701A1 |
A method for preparing dialkyl amino acid ester sulfonates having reduced levels of byproducts, particularly sulfonic acid ester and dialkyl ether, is disclosed. The method involves reacting an amino acid having at least two carboxylic a...
|
|
WO/2023/247268A1 |
The present invention relates to a method for preparing an oligobutyl benzene sulfonate comprising the steps of oligomerization of a butene mix comprising 1-butene and 2-butene to produce an alkene blend which comprises oligobutenes with...
|
|
WO/2023/237382A1 |
The present invention relates to a method for preparing a polyisobutyl benzene sulfonate comprising the steps of alkylation of benzene with a terminal unsaturated polyisobutene to produce a polyisobutyl benzene, sulfonation of the polyis...
|
|
WO/2023/235985A1 |
The present application relates to zwitterion compounds of Formula I, to processes of their preparations, to conjugates thereof, to compositions comprising them and to their use in diagnostics and/or therapy. wherein Q is selected from Q...
|
|
WO/2023/234382A1 |
Provided is a means with which trioxane can be continuously produced at a high yield. Provided is a composition that contains (A) 58.5-65.5 mass% of formaldehyde, (B) 0.7-4.5 mass% of methanesulfonic acid, and (C) less than 0.007 mass%...
|
|
WO/2023/233273A1 |
The present disclosure relates to a process for preparing a salt of 4-hydroxy pentadecyl benzene sulfonic acid. The process comprises reacting 3-N- Pentadecylphenol with sulphuric acid and neutralizing the 4-hydroxy pentadecyl benzene su...
|
|
WO/2023/225144A1 |
The invention provides piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.
|
|
WO/2023/222909A1 |
The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl grou...
|
|
WO/2023/214552A1 |
The present disclosure provides: a trifluoromethane sulfonylation agent composition containing a compound represented by general formula (1) or (11) disclosed in the description; and a method for producing a trifluoromethanesulfonyloxy c...
|
|
WO/2023/210363A1 |
Provided are a water-soluble fluorescent compound having a novel structure, and a method for producing the fluorescent compound. The fluorescent compound is represented by formula (1).
|
|
WO/2023/211889A1 |
The present disclosure provides crystalline forms of the free base and of various salts of the compound of formula A and compositions and methods thereof, useful for treating various conditions in which the Transcriptional Enhancer Assoc...
|
|
WO/2023/205152A1 |
A method of mitigating the formation of 1,4-dioxane and precursors of 1,4-dioxane in alkyl ether sulfate surfactants is disclosed. The method involves adding one or more alcohol, hydrotrope or anti-oxidant additives to an aqueous solutio...
|
|
WO/2023/205757A1 |
Polyhydroxy multiple charged ionic compounds that are the reaction product from either a single amidation and aza-Michael addition reaction or a two-step process of synthesizing a gluconamide intermediate and thereafter undergoing an aza...
|
|
WO/2023/202583A1 |
Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...
|
|
WO/2023/196900A1 |
Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
|
|
WO/2023/189961A1 |
This resist composition contains a resin component (A1) having: a constitutional unit (a01) derived from a compound represented by general formula (a0-1); and a constitutional unit (a02) including a lactone-containing cyclic group or the...
|
|
WO/2023/187044A1 |
A process for the production of a surfactant of formula (I) is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications su...
|
|
WO/2023/187421A1 |
The application relates to the besylate, phosphate, tartrate, fumarate and succinate salts of mesembrine, also known as 3a-(3,4- dimethoxyphenyl)-octahydro-1-methyl-6H-indol-6-one. Mesembrine has the chemical formula C17H23NO3. The appli...
|
|
WO/2023/189503A1 |
The present invention causes a radiation-sensitive composition to contain a polymer including acid-labile group and a compound (Q) given by formula (1). In formula (1), L1 represents an ester group, -CO-NR3-, a (thio) ether group, or a s...
|
|
WO/2023/183601A1 |
This disclosure features methods for preparing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that inhibit epidermal growth factor receptor (EGFR, E...
|
|
WO/2023/179771A1 |
Provided herein are salts and crystalline forms of Compound (I), and salts, solvates, and salt solvates thereof. Also provided herein are pharmaceutical compositions comprising the crystalline forms, and therapeutic uses of the crystalli...
|
|
WO/2023/176209A1 |
A tosylic acid anionic ionic liquid represented by formula (1) is a unique compound that is especially stable in supercooled conditions and maintains a liquid state especially easily, even among ionic liquids, and can be handled as a liq...
|
|
WO/2023/176546A1 |
The present invention provides a resist composition which contains a base material component (A) and a compound (B0) that is represented by general formula (b0). In the formula, Rpg represents an acid-decomposable group; Rl0 represents a...
|
|
WO/2023/173203A1 |
Provided herein is a method for a method for producing an ionizable amino lipid, or a pharmaceutically acceptable salt thereof, the method comprising a nucleophilic displacement of a leaving group L in a compound of Formula (II), wherein...
|
|
WO/2023/171670A1 |
This resist composition, which generates an acid by being exposed to light and of which the solubility in a developer changes due to the action of the acid, contains a resin component (A1) of which the solubility in a developer changes d...
|
|
WO/2023/171597A1 |
Provided are high-purity styrenesulfonic acids having markedly decreased bound bromine and polymers thereof that are useful as modifiers for secondary batteries, dopants for conductive polymers, additives for semiconductor abrasives and ...
|
|
WO/2023/168249A2 |
The invention relates to cysteamides, therapeutic compositions containing such cysteamides and methods of using the same.
|
